Nicole Vaughn, APRN
Psychiatric/Mental Health · Las Vegas, NVNPI 1023469202
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,830 of the $7,997 with a category attached, or 85.4%. 25 manufacturers reported payments, led by Johnson & Johnson at 26.4% of the total. 2025 is the largest year on record at $3,108, 2.3 times the $1,368 reported in 2021. Among psychiatric/mental health clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 335 payments — averaging $23.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- Otsuka America Pharmaceutical, Inc.$811
- AbbVie$801
- Supernus Pharmaceuticals, Inc.$755
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$607
- Alkermes, Inc.$601
- plus $2K from 19 others
What the payments were for
- Travel & lodging$1,16815%
- Food & beverage$6,83085%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 27 | $2,107 |
| Otsuka America Pharmaceutical, Inc. | 43 | $811 |
| AbbVie | 55 | $801 |
| Supernus Pharmaceuticals, Inc. | 49 | $755 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 38 | $607 |
| Alkermes, Inc. | 26 | $601 |
| Neuronetics, Inc. | 5 | $411 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $339 |
| Neurocrine Biosciences, Inc. | 12 | $256 |
| Vanda Pharmaceuticals Inc. | 6 | $181 |
| Indivior Inc. | 7 | $174 |
| Almatica Pharma LLC | 9 | $161 |
| Sunovion Pharmaceuticals Inc. | 9 | $143 |
| Teva Pharmaceuticals USA, Inc. | 5 | $112 |
| Lundbeck LLC | 6 | $104 |
| Axsome Therapeutics, Inc. | 4 | $87 |
| Merck | 4 | $65 |
| E.r. Squibb & Sons, L.L.C. | 2 | $54 |
| Alfasigma USA, Inc. | 2 | $51 |
| Sage Therapeutics, LLC | 3 | $50 |
| Corium, LLC | 2 | $37 |
| Gilead | 1 | $36 |
| Bausch Health US, LLC | 1 | $19 |
| Novo Nordisk | 1 | $18 |
| Eisai Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$1,555
- NEUROSTAR TMS THERAPY SYSTEM$250
- QELBREE$125
- CAPLYTA$125
How this compares
$7,997 in reported general payments places this provider in the 95th percentile of 362 psychiatric/mental health providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 19 | $34,837 |
| Clozapine | 13 | $2,148 |
| Vilazodone Hcl | 11 | $737 |
| Quetiapine Fumarate | 19 | $422 |
| Alprazolam | 64 | $393 |
| Bupropion XlBupropion Hcl | 11 | $386 |
| Sertraline Hcl | 31 | $303 |
| Zolpidem Tartrate | 27 | $214 |
| Benztropine Mesylate | 18 | $176 |
| Buspirone Hcl | 19 | $159 |
| Lamotrigine | 15 | $158 |
| Escitalopram Oxalate | 23 | $137 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 12 | $122 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $811 | $34,83719 claims |
| Almatica Pharma LLCSertraline Hcl | $161 | $30331 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 362 psychiatric/mental health providers in Nevada.
Other psychiatric/mental health in Las Vegas
- Michelle GiddingsLas Vegas$131K
- Patrick ApiladoLas Vegas$19K
- Joshua HamiltonLas Vegas$17K
- Sydney EganLas Vegas$14K
- Ma Victoria EscardaLas Vegas$12K
- Carminia SalvacionLas Vegas$12K
- Valentina AkohLas Vegas$12K
- Angela WilsonLas Vegas$11K
- Michael MathisenLas Vegas$10K
- Edina BorosLas Vegas$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.